Dicerna Expands Lead GalXC(TM) Development Program to Encompass All Forms of Primary Hyperoxaluria (PH) and Reveals New Therapeutic Target for DCR-PHXC

Stock Information for Dicerna Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dicerna Pharmaceuticals Inc.

Dicerna to Present at Noble Capital Markets' NobleCon14
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
Dicerna Announces Proposed Public Offering of Common Stock
Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria
Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Dicerna to Present at the Stifel 2017 Healthcare Conference
Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update
Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.